東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Resveratrol and pterostilbene: A nov...

Kala, Rishabh.

FindBook

Google Book

Amazon

博客來

Resveratrol and pterostilbene: A novel combinatorial epigenetic therapy in targeting triple-negative breast cancer.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Resveratrol and pterostilbene: A novel combinatorial epigenetic therapy in targeting triple-negative breast cancer./
作者:	Kala, Rishabh.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2016,
面頁冊數:	191 p.
附註:	Source: Dissertation Abstracts International, Volume: 78-02(E), Section: B.
Contained By:	Dissertation Abstracts International78-02B(E).
標題:	Oncology. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10149521
ISBN:	9781369046212

Resveratrol and pterostilbene: A novel combinatorial epigenetic therapy in targeting triple-negative breast cancer.
Kala, Rishabh.

Resveratrol and pterostilbene: A novel combinatorial epigenetic therapy in targeting triple-negative breast cancer. - Ann Arbor : ProQuest Dissertations & Theses, 2016 - 191 p.

Source: Dissertation Abstracts International, Volume: 78-02(E), Section: B.

Thesis (Ph.D.)--The University of Alabama at Birmingham, 2016.

Although the majority of breast cancers are estrogen receptor (ER)-positive, progesterone receptor (PGR)-positive and/or HER2 positive, approximately 20% of them are triple-negative and lack ER, PGR and HER2 protein expression. These cancers are robust and hard to treat with conventional hormone therapies. The plant-based dietary compounds resveratrol and pterostilbene (a dimethyl derivative of resveratrol) have been shown to modulate the growth of cancer cells individually via affecting genetic and epigenetic profiles, but none of the studies to date have addressed the effects of these two compounds in combination in targeting triple-negative breast cancers (TNBC). We have discovered a synergistic effect of these two compounds when administered in combination in targeting the viability of TNBC at concentrations close to physiologically achievable doses. The effects were further found to be dose- and time-dependent in inhibiting the growth of TNBC cells via inhibiting the expression of SIRT1. This down regulation of SIRT1 further resulted in a significant reduction in DNA damage response (DDR) and telomerase expression, which was indicated by a significant increase in apoptosis in the TNBC cells. In addition, the combination also resulted in a significant increase in the expression of ERalpha in ERalpha-negative breast cancer cells. This increase in expression was due a time-dependent enrichment of acetyl histone H3lysine9 (H3K9), acetyl H3 and H4 active chromatin markers in the ERalpha promoter region as well as a global decline in 5-methylcytosine (5-mC) levels. To further test the functional reactivation of ERalpha, MDA-MB-157 TNBC cells after combinational treatments were exposed to 48 h of traditional tamoxifen therapy and were found to be sensitive to this treatment, hence highlighting a novel discovery with these two compounds in combination. The combination used in this study was safe and non-toxic to control MCF10A non-tumorigenic breast epithelial cells. Collectively, these findings provide new and safer ways to target TNBCs with the use of these two phytochemicals as a novel therapeutic approach and/or administered as an adjuvant therapy along with currently available tamoxifen treatments.

ISBN: 9781369046212Subjects--Topical Terms:

751006
Oncology.

Resveratrol and pterostilbene: A novel combinatorial epigenetic therapy in targeting triple-negative breast cancer.
LDR:03233nmm a2200301 4500 001 2120951
005 20170724102931.5
008 180830s2016 ||||||||||||||||| ||eng d
020 $a 9781369046212
035 $a (MiAaPQ)AAI10149521
035 $a AAI10149521
040 $a MiAaPQ $c MiAaPQ
100 1 $a Kala, Rishabh. $3 3282926
245 1 0 $a Resveratrol and pterostilbene: A novel combinatorial epigenetic therapy in targeting triple-negative breast cancer.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2016
300 $a 191 p.
500 $a Source: Dissertation Abstracts International, Volume: 78-02(E), Section: B.
500 $a Adviser: Trygve O. Tollefsbol.
502 $a Thesis (Ph.D.)--The University of Alabama at Birmingham, 2016.
520 $a Although the majority of breast cancers are estrogen receptor (ER)-positive, progesterone receptor (PGR)-positive and/or HER2 positive, approximately 20% of them are triple-negative and lack ER, PGR and HER2 protein expression. These cancers are robust and hard to treat with conventional hormone therapies. The plant-based dietary compounds resveratrol and pterostilbene (a dimethyl derivative of resveratrol) have been shown to modulate the growth of cancer cells individually via affecting genetic and epigenetic profiles, but none of the studies to date have addressed the effects of these two compounds in combination in targeting triple-negative breast cancers (TNBC). We have discovered a synergistic effect of these two compounds when administered in combination in targeting the viability of TNBC at concentrations close to physiologically achievable doses. The effects were further found to be dose- and time-dependent in inhibiting the growth of TNBC cells via inhibiting the expression of SIRT1. This down regulation of SIRT1 further resulted in a significant reduction in DNA damage response (DDR) and telomerase expression, which was indicated by a significant increase in apoptosis in the TNBC cells. In addition, the combination also resulted in a significant increase in the expression of ERalpha in ERalpha-negative breast cancer cells. This increase in expression was due a time-dependent enrichment of acetyl histone H3lysine9 (H3K9), acetyl H3 and H4 active chromatin markers in the ERalpha promoter region as well as a global decline in 5-methylcytosine (5-mC) levels. To further test the functional reactivation of ERalpha, MDA-MB-157 TNBC cells after combinational treatments were exposed to 48 h of traditional tamoxifen therapy and were found to be sensitive to this treatment, hence highlighting a novel discovery with these two compounds in combination. The combination used in this study was safe and non-toxic to control MCF10A non-tumorigenic breast epithelial cells. Collectively, these findings provide new and safer ways to target TNBCs with the use of these two phytochemicals as a novel therapeutic approach and/or administered as an adjuvant therapy along with currently available tamoxifen treatments.
590 $a School code: 0005.
650 4 $a Oncology. $3 751006
650 4 $a Pharmacology. $3 634543
650 4 $a Biology. $3 522710
690 $a 0992
690 $a 0419
690 $a 0306
710 2 $a The University of Alabama at Birmingham. $b Biology. $3 2122728
773 0 $t Dissertation Abstracts International $g 78-02B(E).
790 $a 0005
791 $a Ph.D.
792 $a 2016
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10149521